{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:29Z","timestamp":1791559469672,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05949-8","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:26:05Z","timestamp":1790396765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiotoxicity of macrolide antibiotics: a pharmacovigilance study integrating FAERS and JADER databases"],"prefix":"10.1007","author":[{"given":"Lu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"5949_CR1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1164\/rccm.201212-2187OE","volume":"187","author":"RK Albert","year":"2013","unstructured":"Albert RK (2013) \u201cLies, damned lies \u2026\u201d and observational studies in comparative effectiveness research. Am J Respir Crit Care Med 187:1173\u20131177. https:\/\/doi.org\/10.1164\/rccm.201212-2187OE","journal-title":"Am J Respir Crit Care Med"},{"key":"5949_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689\u2013698. https:\/\/doi.org\/10.1056\/NEJMoa1104623","journal-title":"N Engl J Med"},{"key":"5949_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"5949_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013398","volume":"7","author":"E Berni","year":"2017","unstructured":"Berni E, de Voogd H, Halcox JP, Butler CC, Bannister CA, Jenkins-Jones S, Jones B, Ouwens M, Currie CJ (2017) Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open 7:e013398. https:\/\/doi.org\/10.1136\/bmjopen-2016-013398","journal-title":"BMJ Open"},{"key":"5949_CR5","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.jacc.2015.09.029","volume":"66","author":"YJ Cheng","year":"2015","unstructured":"Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, Mei WY, Liu LJ, Long M, Yao FJ, Liu J, Liao XX, Du ZM, Dong YG, Ma H, Xiao HP, Wu SH (2015) The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66:2173\u20132184. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.029","journal-title":"J Am Coll Cardiol"},{"key":"5949_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciu914","volume":"60","author":"HW Chou","year":"2015","unstructured":"Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA (2015) Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and \u03b2-lactam\/\u03b2-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 60:566\u2013577. https:\/\/doi.org\/10.1093\/cid\/ciu914","journal-title":"Clin Infect Dis"},{"key":"5949_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cger.2012.07.003","volume":"28","author":"GV Chow","year":"2012","unstructured":"Chow GV, Marine JE, Fleg JL (2012) Epidemiology of arrhythmias and conduction disorders in older adults. Clin Geriatr 28:539\u2013553. https:\/\/doi.org\/10.1016\/j.cger.2012.07.003","journal-title":"Clin Geriatr"},{"key":"5949_CR8","unstructured":"ClinCalc (2025) Azithromycin - Drug Usage Statistics, United States, 2014\u20132023. https:\/\/clincalc.com\/DrugStats\/Drugs\/Azithromycin. Accessed 15 May 2026."},{"key":"5949_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s0006-3223(98)00043-2","volume":"44","author":"F Curtin","year":"1998","unstructured":"Curtin F, Schulz P (1998) Multiple correlations and Bonferroni\u2019s correction. Biol Psychiatry 44:775\u2013777. https:\/\/doi.org\/10.1016\/s0006-3223(98)00043-2","journal-title":"Biol Psychiatry"},{"key":"5949_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2023","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, Rafaniello C, Capuano A, Poluzzi E, Moretti U, Raschi E (2023) Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul 3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057","journal-title":"Front Drug Saf Regul"},{"key":"5949_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5949_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"5949_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00438-18","author":"E Gorelik","year":"2018","unstructured":"Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I (2018) Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00438-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5949_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1573353","volume":"16","author":"TA Hammad","year":"2025","unstructured":"Hammad TA, Naylor M, Ely DM, Davies S (2025) Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action. Front Pharmacol 16:1573353. https:\/\/doi.org\/10.3389\/fphar.2025.1573353.\u00a0","journal-title":"Front Pharmacol"},{"key":"5949_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287297","volume":"18","author":"S Ide","year":"2023","unstructured":"Ide S, Ishikane M, Aoyagi K, Ono A, Asai Y, Tsuzuki S, Kusama Y, Gu Y, Kodama E, Ohmagari N (2023) Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013-2018. PLoS ONE 18:e0287297. https:\/\/doi.org\/10.1371\/journal.pone.0287297","journal-title":"PLoS ONE"},{"key":"5949_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13098","volume":"83","author":"P In\u00e1cio","year":"2017","unstructured":"In\u00e1cio P, Cavaco A, Airaksinen M (2017) The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol 83:227\u2013246. https:\/\/doi.org\/10.1111\/bcp.13098","journal-title":"Br J Clin Pharmacol"},{"key":"5949_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061478","author":"F Iqbal","year":"2025","unstructured":"Iqbal F, Derouen A, Ren R, Kaye AM, Ahmadzadeh S, Shekoohi S, Kaye AD (2025) Macrolide antibiotic mediated cardiac arrhythmias: emerging concepts and clinical implications. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13061478","journal-title":"Biomedicines"},{"key":"5949_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf123","volume":"7","author":"M Jaboyedoff","year":"2025","unstructured":"Jaboyedoff M, Pl\u00fcss-Suard C, Meyer Sauteur PM, Jenkinson SP, Cassini A, Boillat-Blanco N, Crisinel PA, Angoulvant F (2025) Surge in macrolide dispensing to Swiss children in a period of increased incidence of Mycoplasma pneumoniae detection: an interrupted time-series analysis. JAC-Antimicrob Resist 7:dlaf123. https:\/\/doi.org\/10.1093\/jacamr\/dlaf123","journal-title":"JAC-Antimicrob Resist"},{"key":"5949_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/bmj.38666.653600.55","volume":"332","author":"CM Jespersen","year":"2006","unstructured":"Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Hel\u00f8 OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kj\u00f8ller E, Lind I, Nielsen H, Petersen L, Gluud C (2006) Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 332:22\u201327. https:\/\/doi.org\/10.1136\/bmj.38666.653600.55","journal-title":"BMJ"},{"key":"5949_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"5949_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030420","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM (2022) A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). https:\/\/doi.org\/10.3390\/healthcare10030420","journal-title":"Healthcare (Basel)"},{"key":"5949_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050678","author":"K Kimura","year":"2023","unstructured":"Kimura K, Kikegawa M, Kan Y, Uesawa Y (2023) Identifying crude drugs in Kampo medicines associated with drug-induced liver injury using the Japanese adverse drug event report database: a comprehensive survey. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16050678","journal-title":"Pharmaceuticals (Basel)"},{"key":"5949_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","volume":"50","author":"GE Kirsch","year":"2004","unstructured":"Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM (2004) Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50:93\u2013101. https:\/\/doi.org\/10.1016\/j.vascn.2004.06.003","journal-title":"J Pharmacol Toxicol Methods"},{"key":"5949_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s12012-025-09970-w","volume":"25","author":"Y Kono","year":"2025","unstructured":"Kono Y, Niimura T, Goda M, Ueta S, Kawada K, Miyata K, Aizawa F, Yagi K, Izawa-Ishizawa Y, Ishizawa K (2025) Cardiovascular toxicity profile of macrolides investigated using VigiBase data: a pharmacovigilance study. Cardiovasc Toxicol 25:498\u2013506. https:\/\/doi.org\/10.1007\/s12012-025-09970-w","journal-title":"Cardiovasc Toxicol"},{"key":"5949_CR25","doi-asserted-by":"publisher","unstructured":"Lakhan SE (2026) Early evaluation of the food and drug administration (FDA) adverse event monitoring system (AEMS): an analysis of over 32 million pharmacovigilance reports. Cureus 18:e106259. https:\/\/doi.org\/10.7759\/cureus.106259.","DOI":"10.7759\/cureus.106259"},{"key":"5949_CR26","doi-asserted-by":"publisher","unstructured":"Lazzerini PE, Ginjupalli VKM, Reisqs JB, Bertolozzi I, Cantara S, Castagna MG, Accioli R, D\u2019Errico A, Cartocci A, Cantore A, Salvini V, Verrengia D, Salvadori F, Marzotti T, Capecchi M, Bisogno S, Voglino M, Bernardini S, Qu YS, Laghi-Pasini F, Acampa M, Abbate A, Capecchi PL, Boutjdir M (2025)\u00a0Sex hormone profiles in patients with torsades de pointes ventricular tachycardia: a clinical-electrophysiological translational study. JACC Clin Electrophysiol 11:2376\u20132393. https:\/\/doi.org\/10.1016\/j.jacep.2025.07.009","DOI":"10.1016\/j.jacep.2025.07.009"},{"key":"5949_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1485190","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cui Z, Deng C, Yang C, Shi T (2024) A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front Pharmacol 15:1485190. https:\/\/doi.org\/10.3389\/fphar.2024.1485190.","journal-title":"Front Pharmacol"},{"key":"5949_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol"},{"key":"5949_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122247","volume":"10","author":"K Morimoto","year":"2015","unstructured":"Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K (2015) The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS ONE 10:e0122247. https:\/\/doi.org\/10.1371\/journal.pone.0122247","journal-title":"PLoS ONE"},{"key":"5949_CR30","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJMp1302726","volume":"368","author":"AD Mosholder","year":"2013","unstructured":"Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S (2013) Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 368:1665\u20131668. https:\/\/doi.org\/10.1056\/NEJMp1302726","journal-title":"N Engl J Med"},{"key":"5949_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","volume":"17","author":"M Nishiga","year":"2020","unstructured":"Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 17:543\u2013558. https:\/\/doi.org\/10.1038\/s41569-020-0413-9","journal-title":"Nat Rev Cardiol"},{"key":"5949_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.008074","author":"LA Polgreen","year":"2018","unstructured":"Polgreen LA, Riedle BN, Cavanaugh JE, Girotra S, London B, Schroeder MC, Polgreen PM (2018) Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.117.008074","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"5949_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12879-018-3630-7","volume":"19","author":"DF Postma","year":"2019","unstructured":"Postma DF, Spitoni C, van Werkhoven CH, van Elden LJR, Oosterheert JJ, Bonten MJM (2019) Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. BMC Infect Dis 19:17. https:\/\/doi.org\/10.1186\/s12879-018-3630-7","journal-title":"BMC Infect Dis"},{"key":"5949_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1370\/afm.1601","volume":"12","author":"GA Rao","year":"2014","unstructured":"Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM (2014) Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 12:121\u2013127. https:\/\/doi.org\/10.1370\/afm.1601","journal-title":"Ann Fam Med"},{"key":"5949_CR35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366:1881\u20131890. https:\/\/doi.org\/10.1056\/NEJMoa1003833","journal-title":"N Engl J Med"},{"key":"5949_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/ije\/29.5.837","volume":"29","author":"I Saito","year":"2000","unstructured":"Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T (2000) Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 29:837\u2013844. https:\/\/doi.org\/10.1093\/ije\/29.5.837","journal-title":"Int J Epidemiol"},{"key":"5949_CR37","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","volume":"368","author":"H Svanstr\u00f6m","year":"2013","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A (2013) Use of azithromycin and death from cardiovascular causes. N Engl J Med 368:1704\u20131712. https:\/\/doi.org\/10.1056\/NEJMoa1300799","journal-title":"N Engl J Med"},{"key":"5949_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25:381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001","journal-title":"Drug Saf"},{"key":"5949_CR39","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.7150\/ijms.34141","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR (2019) Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system. Int J Med Sci 16:1018\u20131022. https:\/\/doi.org\/10.7150\/ijms.34141","journal-title":"Int J Med Sci"},{"key":"5949_CR40","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1161\/cir.0000000000000905","volume":"142","author":"JE Tisdale","year":"2020","unstructured":"Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B (2020) Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation 142:e214\u2013e233. https:\/\/doi.org\/10.1161\/cir.0000000000000905","journal-title":"Circulation"},{"key":"5949_CR41","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1503\/cmaj.150901","volume":"188","author":"MH Trac","year":"2016","unstructured":"Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, Garg AX (2016) Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ 188:E120-e129. https:\/\/doi.org\/10.1503\/cmaj.150901","journal-title":"CMAJ"},{"key":"5949_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","volume":"37","author":"PM Tregunno","year":"2014","unstructured":"Tregunno PM, Fink DB, Fernandez-Fernandez C, L\u00e1zaro-Bengoa E, Nor\u00e9n GN (2014) Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf 37:249\u2013258. https:\/\/doi.org\/10.1007\/s40264-014-0146-y","journal-title":"Drug Saf"},{"key":"5949_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.4944","volume":"29","author":"M Tsuchiya","year":"2020","unstructured":"Tsuchiya M, Obara T, Sakai T, Nomura K, Takamura C, Mano N (2020) Quality evaluation of the Japanese Adverse Drug Event Report database (JADER). Pharmacoepidemiol Drug Saf 29:173\u2013181. https:\/\/doi.org\/10.1002\/pds.4944","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5949_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/bcp.70291","volume":"92","author":"M Tsuchiya","year":"2026","unstructured":"Tsuchiya M, Funakoshi R, Masuyama K, Mano N, Hori S, Obara T (2026) Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database. Br J Clin Pharmacol 92:515\u2013524. https:\/\/doi.org\/10.1002\/bcp.70291","journal-title":"Br J Clin Pharmacol"},{"key":"5949_CR45","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s40121-023-00829-7","volume":"12","author":"S Tsuzuki","year":"2023","unstructured":"Tsuzuki S, Koizumi R, Matsunaga N, Ohmagari N (2023) Decline in antimicrobial consumption and stagnation in reducing disease burden due to antimicrobial resistance in Japan. Infect Dis Ther 12:1823\u20131834. https:\/\/doi.org\/10.1007\/s40121-023-00829-7","journal-title":"Infect Dis Ther"},{"key":"5949_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"5949_CR47","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jama.2018.2945","volume":"319","author":"R Voelker","year":"2018","unstructured":"Voelker R (2018) Another caution for clarithromycin. JAMA 319:1314. https:\/\/doi.org\/10.1001\/jama.2018.2945","journal-title":"JAMA"},{"key":"5949_CR48","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/s0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380:660\u2013667. https:\/\/doi.org\/10.1016\/s0140-6736(12)60953-2","journal-title":"Lancet"},{"key":"5949_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6926","volume":"352","author":"AY Wong","year":"2016","unstructured":"Wong AY, Root A, Douglas IJ, Chui CS, Chan EW, Ghebremichael-Weldeselassie Y, Siu CW, Smeeth L, Wong IC (2016) Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 352:h6926. https:\/\/doi.org\/10.1136\/bmj.h6926","journal-title":"BMJ"},{"key":"5949_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1117254","volume":"10","author":"Y Wu","year":"2023","unstructured":"Wu Y, Bi WT, Qu LP, Fan J, Kong XJ, Ji CC, Chen XM, Yao FJ, Liu LJ, Cheng YJ, Wu SH (2023) Administration of macrolide antibiotics increases cardiovascular risk. Front Cardiovasc Med 10:1117254. https:\/\/doi.org\/10.3389\/fcvm.2023.1117254","journal-title":"Front Cardiovasc Med"},{"key":"5949_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00693","volume":"7","author":"T Yamazaki","year":"2016","unstructured":"Yamazaki T, Kenri T (2016) Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 7:693. https:\/\/doi.org\/10.3389\/fmicb.2016.00693","journal-title":"Front Microbiol"},{"key":"5949_CR52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102:688\u2013700. https:\/\/doi.org\/10.1002\/cpt.690","journal-title":"Clin Pharmacol Ther"},{"key":"5949_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103160","volume":"82","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Li Y, Zhu C, Dong Q, Zhang Y, Liu Z, Ren D, Zhao F, Zhao J (2025) Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study. EClinicalMedicine 82:103160. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103160","journal-title":"EClinicalMedicine"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05949-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:02:16Z","timestamp":1790442136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05949-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":53,"alternative-id":["5949"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05949-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"16 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study utilized publicly accessible, fully de-identified data from the FAERS\u00a0and JADER databases, with all personal identifiers removed prior to public release in accordance with FDA and PMDA\u00a0regulations. Thus, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}